Q3 Earnings Forecast for Penumbra Issued By Leerink Partnrs

Penumbra, Inc. (NYSE:PEN) – Analysts at Leerink Partnrs increased their Q3 2025 earnings estimates for shares of Penumbra in a note issued to investors on Thursday, April 24th. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings of $1.00 per share for the quarter, up from their previous forecast of $0.98. The consensus estimate for Penumbra’s current full-year earnings is $3.67 per share. Leerink Partnrs also issued estimates for Penumbra’s Q4 2025 earnings at $1.15 EPS and FY2025 earnings at $3.81 EPS.

Other analysts have also recently issued research reports about the stock. Robert W. Baird upped their target price on shares of Penumbra from $316.00 to $325.00 and gave the company an “outperform” rating in a research report on Thursday, April 24th. Bank of America assumed coverage on Penumbra in a report on Friday, March 14th. They issued a “buy” rating and a $320.00 price objective for the company. UBS Group restated a “buy” rating and set a $330.00 target price (up previously from $320.00) on shares of Penumbra in a report on Thursday, April 24th. Wells Fargo & Company upped their price target on Penumbra from $305.00 to $315.00 and gave the company an “overweight” rating in a research note on Thursday, April 24th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Penumbra in a research note on Wednesday, February 19th. Three research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $302.40.

Penumbra Trading Down 0.2 %

PEN opened at $296.59 on Monday. The firm has a 50 day simple moving average of $276.75 and a 200 day simple moving average of $256.16. Penumbra has a fifty-two week low of $148.00 and a fifty-two week high of $310.00. The company has a market cap of $11.49 billion, a price-to-earnings ratio of 872.32, a price-to-earnings-growth ratio of 2.83 and a beta of 0.56. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25.

Penumbra (NYSE:PEN) last released its earnings results on Wednesday, April 23rd. The company reported $0.83 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.17. The company had revenue of $324.14 million during the quarter, compared to the consensus estimate of $315.72 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The firm’s quarterly revenue was up 16.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.41 earnings per share.

Insider Buying and Selling at Penumbra

In other news, Director Thomas Wilder sold 360 shares of Penumbra stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $264.58, for a total value of $95,248.80. Following the sale, the director now directly owns 4,533 shares in the company, valued at $1,199,341.14. This trade represents a 7.36 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Adam Elsesser sold 61,600 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $283.59, for a total transaction of $17,469,144.00. Following the transaction, the chief executive officer now owns 16,376 shares of the company’s stock, valued at $4,644,069.84. The trade was a 79.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 140,446 shares of company stock valued at $39,543,953 in the last 90 days. 5.00% of the stock is currently owned by company insiders.

Institutional Trading of Penumbra

Several institutional investors and hedge funds have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. acquired a new position in shares of Penumbra during the 4th quarter worth approximately $573,000. E. Ohman J or Asset Management AB grew its stake in shares of Penumbra by 10.4% in the fourth quarter. E. Ohman J or Asset Management AB now owns 21,312 shares of the company’s stock valued at $5,061,000 after buying an additional 2,000 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Penumbra by 1.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 271,574 shares of the company’s stock worth $64,493,000 after buying an additional 3,807 shares during the last quarter. Washington Capital Management Inc. bought a new stake in Penumbra during the fourth quarter worth $226,000. Finally, Allspring Global Investments Holdings LLC lifted its stake in Penumbra by 39.8% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 299,397 shares of the company’s stock valued at $71,831,000 after acquiring an additional 85,284 shares during the last quarter. Institutional investors own 88.88% of the company’s stock.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.